HSP65-HBV多表位融合蛋白乙肝治疗性疫苗的研制
发布时间：2018-11-01 19:21
【摘要】：对于乙型肝炎,目前尚无理想的治疗药物。因此,新型的HBV治疗性疫苗的研制成为国内外的热点研究课题。 新近的研究表明,HSP65可引导与其形成复合物或融合蛋白的抗原肽在树突状细胞内经MHC I类途径加工递呈,从而激活抗原特异性的细胞免疫反应。此外,PADRE是一种Th表位,Th细胞在特异性CTL的产生和维持方面起重要作用。 因此,本文自行设计了一种乙肝治疗性疫苗:卡介苗热休克蛋白65-PADRE-HBV多表位融合蛋白(HSP65-HBV epi)。 该融合蛋白可在小鼠体内诱生HBV特异性CTLs,刺激代表Th1途径的IgG2a抗体的产生;可在体外刺激人DCs的成熟,并可通过DCs促进自体CD8+ T细胞的增生并诱导HBV特异性CTLs的产生,这些特异性CTLs具有分泌IFN-γ的能力。 因此,HSP65-HBV epi融合蛋白非常有希望成为有效的乙肝治疗性疫苗。
[Abstract]:There is no ideal therapy for hepatitis B. Therefore, the development of new HBV therapeutic vaccine has become a hot research topic at home and abroad. Recent studies have shown that HSP65 can induce antigenic peptides to form complexes or fusion proteins in dendritic cells via MHC I pathway to activate antigen-specific cellular immune responses. In addition, PADRE is a Th epitope, and Th cells play an important role in the production and maintenance of specific CTL. Therefore, we designed a therapeutic hepatitis B vaccine: BCG heat shock protein 65-PADRE-HBV multiepitope fusion protein (HSP65-HBV epi). The fusion protein could induce HBV specific CTLs, to stimulate the production of IgG2a antibody representing the Th1 pathway in mice. It can stimulate the maturation of human DCs in vitro, promote the proliferation of autologous CD8 T cells through DCs and induce the production of HBV specific CTLs. These specific CTLs have the ability to secrete IFN- 纬. Therefore, HSP65-HBV epi fusion protein is very promising as an effective therapeutic vaccine for hepatitis B.
【学位授予单位】：吉林大学
【学位级别】：博士
【学位授予年份】：2006
【分类号】：R392
本文编号：2304867
[Abstract]:There is no ideal therapy for hepatitis B. Therefore, the development of new HBV therapeutic vaccine has become a hot research topic at home and abroad. Recent studies have shown that HSP65 can induce antigenic peptides to form complexes or fusion proteins in dendritic cells via MHC I pathway to activate antigen-specific cellular immune responses. In addition, PADRE is a Th epitope, and Th cells play an important role in the production and maintenance of specific CTL. Therefore, we designed a therapeutic hepatitis B vaccine: BCG heat shock protein 65-PADRE-HBV multiepitope fusion protein (HSP65-HBV epi). The fusion protein could induce HBV specific CTLs, to stimulate the production of IgG2a antibody representing the Th1 pathway in mice. It can stimulate the maturation of human DCs in vitro, promote the proliferation of autologous CD8 T cells through DCs and induce the production of HBV specific CTLs. These specific CTLs have the ability to secrete IFN- 纬. Therefore, HSP65-HBV epi fusion protein is very promising as an effective therapeutic vaccine for hepatitis B.
【学位授予单位】：吉林大学
【学位级别】：博士
【学位授予年份】：2006
【分类号】：R392
【相似文献】
相关博士学位论文 前1条
1 王华;HSP65-HBV多表位融合蛋白乙肝治疗性疫苗的研制[D];吉林大学;2006年
，本文编号：2304867
本文链接：https://www.wllwen.com/yixuelunwen/binglixuelunwen/2304867.html
最近更新
教材专著
